Post-pelvic inflammatory disease sequelae · Chronic pelvic pain
Conditions
Interventions
Low-dose group:(Shenpu Penyan Granules 1 packet + Shenpu Penyan Granules placebo 2 packets) per dose, orally, 3 times daily.
Mid-dose group:(Shenpu Benyan Granules 2 packets + Shenpu Benyan Granules placebo 1 packet) per dose, orally, 3 times daily.
High-dose group:Shenpu Pienyan Granules, 3 packets per dose, by mouth, 3 times daily.
Placebo group:Shenpu Pianyan Granule Simulant, 3 packets per dose, oral administration, 3 times daily.
Sponsors
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria for post-inflammatory sequelae of pelvic inflammatory disease in Western medicine; 2. Meets the diagnostic criteria for damp-heat and blood stasis syndrome in traditional Chinese medicine; 3. Age between 18 and 50 years, married or unmarried patients with a history of sexual activity; 4. Patients with regular menstrual cycles (menstrual cycle of 21-35 days); 5. Voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with acute pelvic inflammatory diseases; 2. Patients confirmed by examination to have symptoms caused by gynecological tumors (excluding uterine fibroids smaller than 3 cm), specific vaginitis (e.g., vulvovaginal candidiasis, trichomoniasis, bacterial vaginosis), endometriosis, adenomyosis, tuberculous pelvic inflammation, pelvic abscess, pelvic mass, cervical lesions, or other conditions; 3. Patients without a uterus or without one or both adnexa; 4. Pregnant women or women planning pregnancy within the next six months, or breastfeeding women; 5. Patients with severe primary diseases such as serious heart, cerebrovascular, liver, kidney, or hematological disorders, diabetes, thyroid diseases, or mental illness; 6. Patients with a history of allergies or hypersensitivity to any components of this medication; 7. Patients who have participated in other clinical studies within the past month or are currently using similar drugs or related treatments, such as antibiotics, which may affect the assessment of drug efficacy; 8. Patients with suspected or confirmed alcohol addiction, drug abuse history, or other conditions that may reduce the likelihood of enrollment or complicate participation, such as frequent changes in work or living environments, which may lead to loss to follow-up; 9. Patients deemed unsuitable for participation in this clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abdominal/Lumbosacral Pain Visual Analogue Scale( VAS) Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| McCormack Scale Score;Traditional Chinese Medicine syndrome score;Quality of Life SF-36 Brief Health Survey Scoring; | — |
Countries
China
Contacts
Public ContactSong Dianrong
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Outcome results
None listed